Participants
NSCLC, Tumor, non-small-cell lung cancer, Tumors, Cancer
TUMOR, TUMORS, WEST, NSCLC, CANCER
This study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The study protocol and all amendments were approved by institutional review boards at all participating sites, including Sun Yat-sen University Cancer Center, Fujian Cancer Hospital, Shanghai Chest Hospital, Zhejiang Cancer Hospital, Shanxi Provincial Cancer Hospital, West China Hospital, Hunan Cancer Hospital, Chinese PLA General Hospital, Henan Cancer Hospital, Union Hospital of Tongji Medical College, Hebei Tumor Hospital, Nanjing Drum Tower Hospital, Jiangsu Province Hospital of Chinese Medicine, Shanxi Bethune Hospital and Renmin Hospital of Wuhan University. All patients provided written informed consent before enrollment.Eligible patients were aged ≥18 years, had histologically or cytologically confirmed stage IIIB or IV non-small-cell lung cancer (NSCLC) harboring EGFR exon 20 insertions (20ins), had at least one measurable lesion defined by Response Evaluation Criteria in Solid Tumors v.1.1 (RECIST v.1.1)